Concepts (192)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Antiretroviral Therapy, Highly Active | 6 | 2020 | 952 | 1.23 | Why? |
| European Union | 3 | 2019 | 565 | 0.75 | Why? |
| Nucleosides | 1 | 2021 | 221 | 0.72 | Why? |
| Heart Valves | 1 | 2018 | 52 | 0.70 | Why? |
| Darunavir | 2 | 2021 | 477 | 0.69 | Why? |
| AIDS Dementia Complex | 1 | 2017 | 48 | 0.65 | Why? |
| Raltegravir Potassium | 1 | 2017 | 132 | 0.64 | Why? |
| HIV Infections | 13 | 2020 | 11620 | 0.62 | Why? |
| Q Fever | 1 | 2018 | 130 | 0.62 | Why? |
| Prisons | 4 | 2019 | 980 | 0.60 | Why? |
| Developed Countries | 1 | 2019 | 500 | 0.58 | Why? |
| Anti-HIV Agents | 5 | 2019 | 2209 | 0.57 | Why? |
| Prosthesis-Related Infections | 1 | 2018 | 302 | 0.53 | Why? |
| Ritonavir | 6 | 2021 | 4212 | 0.52 | Why? |
| Lamivudine | 3 | 2021 | 210 | 0.51 | Why? |
| Endocarditis, Bacterial | 1 | 2018 | 344 | 0.49 | Why? |
| Atazanavir Sulfate | 3 | 2021 | 213 | 0.48 | Why? |
| Adipose Tissue | 1 | 2018 | 612 | 0.48 | Why? |
| Heart Valve Prosthesis | 1 | 2018 | 533 | 0.46 | Why? |
| Heart Valve Prosthesis Implantation | 1 | 2018 | 552 | 0.45 | Why? |
| Drug Therapy, Combination | 5 | 2021 | 7268 | 0.44 | Why? |
| Early Detection of Cancer | 1 | 2020 | 1956 | 0.37 | Why? |
| Emtricitabine | 2 | 2021 | 202 | 0.36 | Why? |
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 1458 | 0.35 | Why? |
| Protease Inhibitors | 2 | 2021 | 3630 | 0.29 | Why? |
| Angiotensin Receptor Antagonists | 2 | 2021 | 3892 | 0.29 | Why? |
| Viral Load | 5 | 2021 | 15850 | 0.27 | Why? |
| HIV-1 | 5 | 2018 | 3365 | 0.25 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 5277 | 0.24 | Why? |
| Olfaction Disorders | 4 | 2021 | 3704 | 0.24 | Why? |
| Integrase Inhibitors | 2 | 2018 | 27 | 0.23 | Why? |
| Prisoners | 2 | 2021 | 738 | 0.22 | Why? |
| Heterocyclic Compounds, 3-Ring | 3 | 2018 | 275 | 0.20 | Why? |
| Vaccines, Combined | 1 | 2019 | 67 | 0.19 | Why? |
| HIV-Associated Lipodystrophy Syndrome | 1 | 2018 | 15 | 0.19 | Why? |
| Sensory Thresholds | 1 | 2020 | 115 | 0.19 | Why? |
| Boutonneuse Fever | 1 | 2018 | 21 | 0.18 | Why? |
| Rilpivirine | 1 | 2018 | 65 | 0.18 | Why? |
| Absorptiometry, Photon | 1 | 2018 | 168 | 0.17 | Why? |
| Early Medical Intervention | 1 | 2021 | 487 | 0.17 | Why? |
| CD4 Lymphocyte Count | 2 | 2019 | 1517 | 0.16 | Why? |
| Health Services Accessibility | 1 | 2020 | 10697 | 0.16 | Why? |
| Cholangiocarcinoma | 1 | 2019 | 186 | 0.16 | Why? |
| Cobicistat | 1 | 2017 | 172 | 0.16 | Why? |
| Lopinavir | 2 | 2021 | 4308 | 0.16 | Why? |
| Bile Duct Neoplasms | 1 | 2019 | 172 | 0.15 | Why? |
| Quinolones | 1 | 2017 | 167 | 0.15 | Why? |
| Drug Utilization | 1 | 2021 | 619 | 0.15 | Why? |
| Reverse Transcriptase Inhibitors | 1 | 2017 | 309 | 0.14 | Why? |
| Antiviral Agents | 4 | 2021 | 41703 | 0.14 | Why? |
| Italy | 11 | 2021 | 38444 | 0.14 | Why? |
| Drug Substitution | 1 | 2018 | 385 | 0.14 | Why? |
| Vaccination | 2 | 2021 | 19050 | 0.14 | Why? |
| Delphi Technique | 1 | 2019 | 1257 | 0.14 | Why? |
| Body Composition | 1 | 2018 | 414 | 0.13 | Why? |
| Alanine Transaminase | 1 | 2020 | 1329 | 0.13 | Why? |
| Tenofovir | 1 | 2017 | 449 | 0.13 | Why? |
| Proportional Hazards Models | 3 | 2021 | 6543 | 0.13 | Why? |
| Aspartate Aminotransferases | 1 | 2020 | 1394 | 0.13 | Why? |
| Drug Combinations | 2 | 2021 | 3852 | 0.13 | Why? |
| Neoplasms | 2 | 2021 | 17251 | 0.12 | Why? |
| Ageusia | 1 | 2020 | 918 | 0.12 | Why? |
| Humans | 37 | 2021 | 930598 | 0.11 | Why? |
| Lymphocyte Count | 2 | 2021 | 4758 | 0.11 | Why? |
| Oxazines | 3 | 2018 | 279 | 0.11 | Why? |
| Antineoplastic Agents, Immunological | 1 | 2019 | 830 | 0.11 | Why? |
| Coronavirus | 1 | 2021 | 18339 | 0.11 | Why? |
| Patient Acceptance of Health Care | 3 | 2019 | 5002 | 0.11 | Why? |
| Lipids | 1 | 2018 | 1079 | 0.11 | Why? |
| Kaplan-Meier Estimate | 1 | 2020 | 4260 | 0.11 | Why? |
| Homes for the Aged | 1 | 2021 | 1071 | 0.10 | Why? |
| Continuity of Patient Care | 1 | 2020 | 1574 | 0.10 | Why? |
| Male | 23 | 2021 | 367725 | 0.10 | Why? |
| Fluorodeoxyglucose F18 | 1 | 2018 | 1153 | 0.10 | Why? |
| Piperazines | 3 | 2018 | 445 | 0.10 | Why? |
| Molecular Targeted Therapy | 1 | 2019 | 1579 | 0.10 | Why? |
| Sexually Transmitted Diseases | 1 | 2017 | 694 | 0.10 | Why? |
| Early Diagnosis | 1 | 2018 | 2443 | 0.09 | Why? |
| Hepatitis C, Chronic | 1 | 2018 | 973 | 0.09 | Why? |
| Taste Disorders | 1 | 2020 | 1720 | 0.09 | Why? |
| Delivery of Health Care | 3 | 2020 | 15909 | 0.09 | Why? |
| Female | 22 | 2021 | 380317 | 0.09 | Why? |
| Retrospective Studies | 8 | 2021 | 105322 | 0.09 | Why? |
| Enzyme Inhibitors | 1 | 2019 | 1881 | 0.09 | Why? |
| Middle Aged | 19 | 2021 | 270681 | 0.09 | Why? |
| Pyridones | 3 | 2018 | 738 | 0.08 | Why? |
| Aged, 80 and over | 7 | 2021 | 88759 | 0.08 | Why? |
| Hepatitis C | 1 | 2018 | 1514 | 0.08 | Why? |
| Nursing Homes | 2 | 2021 | 4155 | 0.08 | Why? |
| Coronavirus Infections | 5 | 2021 | 253789 | 0.08 | Why? |
| Cost of Illness | 1 | 2017 | 1903 | 0.08 | Why? |
| Hypoxia | 1 | 2021 | 3626 | 0.08 | Why? |
| Cohort Studies | 6 | 2020 | 36005 | 0.08 | Why? |
| Immunotherapy | 1 | 2019 | 2421 | 0.07 | Why? |
| Molecular Docking Simulation | 1 | 2021 | 6902 | 0.07 | Why? |
| Risk Factors | 6 | 2021 | 71621 | 0.07 | Why? |
| Metabolic Diseases | 1 | 2010 | 505 | 0.07 | Why? |
| Radiography, Thoracic | 1 | 2020 | 5486 | 0.06 | Why? |
| Adenosine Monophosphate | 1 | 2021 | 5652 | 0.06 | Why? |
| Alanine | 1 | 2021 | 5687 | 0.06 | Why? |
| Communicable Diseases | 1 | 2018 | 2148 | 0.06 | Why? |
| Diagnosis, Differential | 1 | 2018 | 7220 | 0.06 | Why? |
| Length of Stay | 1 | 2021 | 11042 | 0.06 | Why? |
| HIV | 1 | 2010 | 1116 | 0.06 | Why? |
| Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 3832 | 0.06 | Why? |
| L-Lactate Dehydrogenase | 2 | 2021 | 1995 | 0.06 | Why? |
| Treatment Failure | 2 | 2019 | 2106 | 0.06 | Why? |
| Longitudinal Studies | 1 | 2018 | 9893 | 0.06 | Why? |
| Comorbidity | 3 | 2020 | 34796 | 0.06 | Why? |
| Targeted Gene Repair | 1 | 2019 | 2 | 0.05 | Why? |
| Aged | 10 | 2021 | 215776 | 0.05 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.05 | Why? |
| Diagnostic Equipment | 1 | 2019 | 41 | 0.05 | Why? |
| Feedback, Physiological | 1 | 2019 | 56 | 0.05 | Why? |
| Alkynes | 1 | 2018 | 98 | 0.05 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.05 | Why? |
| Benzoxazines | 1 | 2018 | 103 | 0.04 | Why? |
| X-Rays | 1 | 2020 | 492 | 0.04 | Why? |
| Maximum Tolerated Dose | 1 | 2017 | 65 | 0.04 | Why? |
| Adult | 11 | 2020 | 244371 | 0.04 | Why? |
| Sensitivity and Specificity | 1 | 2018 | 22971 | 0.04 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 2019 | 260 | 0.04 | Why? |
| Sustained Virologic Response | 1 | 2018 | 378 | 0.04 | Why? |
| Risk Assessment | 1 | 2021 | 25439 | 0.04 | Why? |
| Hospital Mortality | 1 | 2020 | 22087 | 0.04 | Why? |
| Cyclopropanes | 1 | 2018 | 332 | 0.04 | Why? |
| RNA, Viral | 3 | 2018 | 32276 | 0.04 | Why? |
| HIV Integrase Inhibitors | 1 | 2017 | 173 | 0.04 | Why? |
| Hypertension | 1 | 2017 | 8895 | 0.04 | Why? |
| Prevalence | 4 | 2021 | 25773 | 0.04 | Why? |
| Fibrin Fibrinogen Degradation Products | 2 | 2021 | 5993 | 0.03 | Why? |
| C-Reactive Protein | 2 | 2021 | 7972 | 0.03 | Why? |
| Coinfection | 3 | 2019 | 6820 | 0.03 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 8811 | 0.03 | Why? |
| Lipid Metabolism | 1 | 2018 | 572 | 0.03 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.03 | Why? |
| Prospective Studies | 4 | 2021 | 43301 | 0.03 | Why? |
| Ferritins | 1 | 2021 | 2055 | 0.03 | Why? |
| Hospitalization | 2 | 2020 | 54280 | 0.03 | Why? |
| Treatment Outcome | 4 | 2019 | 51732 | 0.03 | Why? |
| Heparin, Low-Molecular-Weight | 1 | 2021 | 1731 | 0.03 | Why? |
| Smell | 1 | 2021 | 1851 | 0.03 | Why? |
| Interdisciplinary Communication | 1 | 2019 | 1425 | 0.03 | Why? |
| Child | 1 | 2021 | 70012 | 0.03 | Why? |
| Lung | 1 | 2020 | 31049 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2018 | 2324 | 0.03 | Why? |
| Pandemics | 5 | 2021 | 389249 | 0.03 | Why? |
| Leukocyte Count | 1 | 2020 | 3178 | 0.03 | Why? |
| Lung Neoplasms | 1 | 2007 | 3228 | 0.03 | Why? |
| Health Care Costs | 1 | 2018 | 1007 | 0.03 | Why? |
| Multivariate Analysis | 1 | 2020 | 5440 | 0.02 | Why? |
| Safety | 1 | 2017 | 1583 | 0.02 | Why? |
| Communicable Disease Control | 1 | 2018 | 29620 | 0.02 | Why? |
| ROC Curve | 1 | 2020 | 6024 | 0.02 | Why? |
| Sexual Behavior | 1 | 2017 | 1322 | 0.02 | Why? |
| Dyspnea | 1 | 2021 | 3847 | 0.02 | Why? |
| Noninvasive Ventilation | 1 | 2020 | 2329 | 0.02 | Why? |
| Oxygen Inhalation Therapy | 1 | 2020 | 3629 | 0.02 | Why? |
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 3633 | 0.02 | Why? |
| Homeless Persons | 1 | 2017 | 1171 | 0.02 | Why? |
| Survival Rate | 1 | 2021 | 9206 | 0.02 | Why? |
| Symptom Assessment | 1 | 2020 | 4967 | 0.02 | Why? |
| Blood Pressure | 1 | 2017 | 2198 | 0.02 | Why? |
| Transients and Migrants | 1 | 2017 | 1468 | 0.02 | Why? |
| Syndrome | 1 | 2010 | 1310 | 0.02 | Why? |
| Fever | 1 | 2021 | 7795 | 0.02 | Why? |
| Body Mass Index | 1 | 2017 | 4306 | 0.02 | Why? |
| Cardiovascular Diseases | 2 | 2020 | 11497 | 0.02 | Why? |
| Sex Factors | 1 | 2021 | 11014 | 0.02 | Why? |
| Substance-Related Disorders | 1 | 2017 | 2038 | 0.02 | Why? |
| Interleukin-6 | 1 | 2021 | 7522 | 0.02 | Why? |
| Databases, Factual | 1 | 2017 | 6248 | 0.01 | Why? |
| Signal Transduction | 1 | 2019 | 7207 | 0.01 | Why? |
| Europe | 1 | 2018 | 12702 | 0.01 | Why? |
| Sex Distribution | 1 | 2007 | 2083 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2019 | 7330 | 0.01 | Why? |
| Inflammation | 1 | 2021 | 13255 | 0.01 | Why? |
| Quality of Life | 1 | 2019 | 9820 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.01 | Why? |
| Odds Ratio | 1 | 2010 | 5861 | 0.01 | Why? |
| Mental Disorders | 1 | 2021 | 6742 | 0.01 | Why? |
| Biomarkers | 1 | 2021 | 23361 | 0.01 | Why? |
| Young Adult | 2 | 2020 | 93724 | 0.01 | Why? |
| Prognosis | 1 | 2020 | 32490 | 0.01 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.01 | Why? |
| Time Factors | 1 | 2020 | 31397 | 0.01 | Why? |
| Age Factors | 1 | 2017 | 21039 | 0.01 | Why? |
| Anti-Bacterial Agents | 1 | 2017 | 10083 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.01 | Why? |
| Incidence | 1 | 2017 | 25622 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2019 | 43792 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2010 | 53120 | 0.00 | Why? |
Madeddu's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(192)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(112)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_